It’s no secret that the high cost of healthcare is a significant concern for most Americans. The total national health expenditure in 2021 increased by 2.7% from the previous year to 4.3 trillion dollars which was 18.3% of the gross domestic product. The federal government held the majority of the spending burden at 34%, with individual households a close second at 27%. A cornerstone component of medical treatment is the access to prescription drugs. In 2019 in the U.S., the government and private insurers spent twice as much on prescription drugs as in other comparatively wealthy countries. Despite catchy phrases that poll well, and “simple” solutions by politicians that promise to fix the problem—such as Prescription Drug Advisory Boards (PDABs)—it is mindful to remember one thing: if it sounds good to be true, then it probably isn’t true.

Join the Community Access National Network (CANN) on Wednesday, November 1st from 2:00 PM ET to 3:30 PM ET for a webinar dedicated to better understanding what are PDABs, and why they matter to patients. Registration is free and open to patients, advocates, and all public health stakeholders!

The webinar will provide a national, state-by-state, patient-facing discussion on policies, programs, activities, and news on recent state-level efforts to set drug prices and reimbursement rates, and could affect providers, patients, and access to care and medication. While various public and private evaluative actors already engage in negotiating medication list-prices and reimbursement rates, PDABs pose the potential to undermine determinative factors, such as treatment guidelines and efficacy and tolerability as demonstrated in non-inferiority studies, in favor of an arbitrary financial factor. Most notably, financial factors PDABs seek to determine do not necessarily have a direct relationship with patient out-of-pocket costs. As such there is no sufficient evidence to support the notion that reduction in list-prices or reimbursement rates benefit patients. To the contrary, due to various rebate and public health funding schemes which may be dependent on revenues generated from these rebate models, arbitrary price-setting policies risk negatively impacting patient access to care and necessarily disrupt the provider-patient relationship.

Presenters include:

  • Jen Laws, President & CEO at Community Access National Network (CANN)
  • Scott Bertani, Director of Public Policy at HealthHIV

For additional information, please email us at info@tiicann.org.

Prescription Drug Advisory Boards (PDABs): What They Are and Why They Matter to Patients

  • November 1, 2023
  • Cisco WebEx Virtual Meeting
    United States